A. Bonasera

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

B. Vincenzi, M. Novelli, M. Pantaleo, 2021, ESMO open.

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement

V. Bazan, V. Gristina, A. Galvano, 2022, Therapeutic advances in medical oncology.

Controlling the worldwide chaotic spreading of COVID-19 through vaccinations

A. Bonasera, H. Zheng, 2021, medRxiv.

Sodium Propionate Contributes to Tumor Cell Growth Inhibition through PPAR-γ Signaling

S. Cuzzocrea, C. Colarossi, E. Esposito, 2022, Cancers.

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming

A. Russo, V. Bazan, J. Iovanna, 2020, Cancers.

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?

A. Russo, V. Bazan, J. Iovanna, 2021, Cancers.

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

V. Bazan, A. Florena, V. Gristina, 2023, Frontiers in Oncology.

Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)

A. Russo, V. Bazan, G. Pantuso, 2021, Therapeutic advances in medical oncology.